Hurwitz, H., Crocenzi, T., Lohr, J., Bonvini, E., Johnson, S., Moore, P., & Wigginton, J. (2014). A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma. J Immunother Cancer.

Hurwitz, Herbert, Todd Crocenzi, Joanna Lohr, Ezio Bonvini, Syd Johnson, Paul Moore, and Jon Wigginton. "A Phase I, First-in-human, Open Label, Dose Escalation Study of MGD007, a Humanized GpA33 × CD3 Dual-affinity Re-targeting (DART(®)) Protein in Patients With Relapsed/refractory Metastatic Colorectal Carcinoma." J Immunother Cancer 2014.

Hurwitz, Herbert, et al. "A Phase I, First-in-human, Open Label, Dose Escalation Study of MGD007, a Humanized GpA33 × CD3 Dual-affinity Re-targeting (DART(®)) Protein in Patients With Relapsed/refractory Metastatic Colorectal Carcinoma." J Immunother Cancer 2014.